We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
Read MoreHide Full Article
Eyenovia, Inc. (EYEN - Free Report) announced the decision to terminate a phase III study evaluating its investigational drug-device product, MicroPine, as a potential treatment for pediatric progressive myopia. MicroPine is EYEN’s proprietary drug-device combination of low-dose atropine administered using the company’s Optejet dispensing platform.
The decision was taken after an independent Data Review Committee (DRC) determined that the phase III CHAPERONE study of MicroPine was unlikely to meet its primary endpoint of less than 0.5 diopter progression in visual acuity over three years.
The DRC evaluated safety and efficacy data from 252 patients and found no significant difference in myopia progression between the two treatment groups (0.01% and 0.1% atropine ophthalmic metered spray) and placebo. However, all doses of the candidate and the placebo were well-tolerated in the CHAPERONE study, with only mild and infrequent adverse events. The complete study data is yet to be provided to Eyenovia.
Based on this DRC feedback, Eyenovia has decided to terminate the phase III CHAPERONE study of MicroPine for the myopia indication. The company is currently gearing up for a thorough review of the study data to evaluate next steps.
The stock plunged 70% on Friday following the news. Year to date, shares of EYEN have plunged 95.1% compared with the industry’s 10.5% decline.
Image Source: Zacks Investment Research
The company further reported that it is also exploring ways to maximize stakeholder value, cut costs and assess strategic options, which may include a business combination, reverse merger, asset sales, or a combination of these. Additional details will be shared after the evaluation is complete.
EYEN’s Marketed Portfolio of Drugs
The company currently has two FDA-approved products, Mydcombi and clobetasol propionate, which are indicated for in-office pupil dilation and post-ocular inflammation and pain, respectively. Both drugs are yet to gain traction in the market.
Mydcombi received FDA approval in May 2023 for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. The drug was launched in the U.S. market in August 2023. Clobetasol propionate, on the other hand, was only approved by the FDA in March 2024 and subsequently launched in the United States during the third quarter of 2024.
Apart from MicroPine, Eyenovia’s clinical-stage pipeline comprises a few other candidates that are currently undergoing mid-stage development for various dry eye indications.
Allogene Therapeutics’ loss estimates per share have narrowed from $1.40 to $1.35 for 2024 over the past 60 days, while that for 2025 has narrowed from $1.46 to $1.34. ALLO shares have lost 29.3% year to date.
Allogene Therapeutics’ earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 9.42%.
Pfizer’s earnings estimates have risen from $2.62 to $2.88 per share for 2024 over the past 60 days, while that for 2025 has increased from $2.85 to $2.92. PFE shares have lost 13.9% year to date.
Pfizer’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%.
Gilead Sciences’ earnings estimates have risen from $3.79 to $4.28 per share for 2024 over the past 60 days, while that for 2025 has increased from $7.24 to $7.40. GILD shares have risen 9.1% year to date.
Gilead Sciences’ earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.46%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
Eyenovia, Inc. (EYEN - Free Report) announced the decision to terminate a phase III study evaluating its investigational drug-device product, MicroPine, as a potential treatment for pediatric progressive myopia. MicroPine is EYEN’s proprietary drug-device combination of low-dose atropine administered using the company’s Optejet dispensing platform.
The decision was taken after an independent Data Review Committee (DRC) determined that the phase III CHAPERONE study of MicroPine was unlikely to meet its primary endpoint of less than 0.5 diopter progression in visual acuity over three years.
The DRC evaluated safety and efficacy data from 252 patients and found no significant difference in myopia progression between the two treatment groups (0.01% and 0.1% atropine ophthalmic metered spray) and placebo. However, all doses of the candidate and the placebo were well-tolerated in the CHAPERONE study, with only mild and infrequent adverse events. The complete study data is yet to be provided to Eyenovia.
Based on this DRC feedback, Eyenovia has decided to terminate the phase III CHAPERONE study of MicroPine for the myopia indication. The company is currently gearing up for a thorough review of the study data to evaluate next steps.
The stock plunged 70% on Friday following the news. Year to date, shares of EYEN have plunged 95.1% compared with the industry’s 10.5% decline.
Image Source: Zacks Investment Research
The company further reported that it is also exploring ways to maximize stakeholder value, cut costs and assess strategic options, which may include a business combination, reverse merger, asset sales, or a combination of these. Additional details will be shared after the evaluation is complete.
EYEN’s Marketed Portfolio of Drugs
The company currently has two FDA-approved products, Mydcombi and clobetasol propionate, which are indicated for in-office pupil dilation and post-ocular inflammation and pain, respectively. Both drugs are yet to gain traction in the market.
Mydcombi received FDA approval in May 2023 for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. The drug was launched in the U.S. market in August 2023. Clobetasol propionate, on the other hand, was only approved by the FDA in March 2024 and subsequently launched in the United States during the third quarter of 2024.
Apart from MicroPine, Eyenovia’s clinical-stage pipeline comprises a few other candidates that are currently undergoing mid-stage development for various dry eye indications.
Eyenovia, Inc. Price and Consensus
Eyenovia, Inc. price-consensus-chart | Eyenovia, Inc. Quote
EYEN’s Zacks Rank and Other Stocks to Consider
Eyenovia currently carries a Zacks Rank #2 (Buy).
Some other top-ranked pharma stocks are Allogene Therapeutics (ALLO - Free Report) , Pfizer (PFE - Free Report) and Gilead Sciences (GILD - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Allogene Therapeutics’ loss estimates per share have narrowed from $1.40 to $1.35 for 2024 over the past 60 days, while that for 2025 has narrowed from $1.46 to $1.34. ALLO shares have lost 29.3% year to date.
Allogene Therapeutics’ earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 9.42%.
Pfizer’s earnings estimates have risen from $2.62 to $2.88 per share for 2024 over the past 60 days, while that for 2025 has increased from $2.85 to $2.92. PFE shares have lost 13.9% year to date.
Pfizer’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%.
Gilead Sciences’ earnings estimates have risen from $3.79 to $4.28 per share for 2024 over the past 60 days, while that for 2025 has increased from $7.24 to $7.40. GILD shares have risen 9.1% year to date.
Gilead Sciences’ earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.46%.